1,714 reports of this reaction
3.3% of all TICAGRELOR reports
#3 most reported adverse reaction
DEATH is the #3 most commonly reported adverse reaction for TICAGRELOR, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,714 FDA adverse event reports linking TICAGRELOR to DEATH. This represents approximately 3.3% of all 52,671 adverse event reports for this drug.
TICAGRELOR has an overall safety score of 85 out of 100. Patients taking TICAGRELOR who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among TICAGRELOR users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for TICAGRELOR:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 1,714 FDA reports for TICAGRELOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 3.3% of all adverse event reports for TICAGRELOR, making it one of the most commonly reported side effect.
If you experience death while taking TICAGRELOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.